| 王秋棠,刘 斐,马晓华,陈 颖,李薛梅.参芍胶囊联合单硝酸异山梨酯片治疗不稳定型心绞痛的疗效及对TLRs/MyD88/NF-κB信号通路的影响[J].,2021,(23):4500-4504 |
| 参芍胶囊联合单硝酸异山梨酯片治疗不稳定型心绞痛的疗效及对TLRs/MyD88/NF-κB信号通路的影响 |
| Curative Effect of Shenshao Capsule Combined with Isosorbide Mononitrate Tablet in the Treatment of Unstable Angina Pectoris and its Effect on TLRs / MyD88 / NF-κB Signaling Pathway |
| 投稿时间：2021-04-05 修订日期：2021-04-27 |
| DOI：10.13241/j.cnki.pmb.2021.23.021 |
| 中文关键词: 参芍胶囊 单硝酸异山梨酯片 不稳定型心绞痛 疗效 TLRs/MyD88/NF-κB信号通路 |
| 英文关键词: Shenshao capsule Isosorbide mononitrate tablet Unstable angina pectoris Curative effect TLRs/MyD88/NF-κB signaling pathway |
| 基金项目:江苏省科技厅基础研究计划项目（BK20170415） |
|
| 摘要点击次数: 873 |
| 全文下载次数: 498 |
| 中文摘要: |
| 摘要 目的：观察参芍胶囊联合单硝酸异山梨酯片治疗不稳定型心绞痛（UAP）的疗效及对TLRs/MyD88/NF-κB信号通路的影响。方法：纳入我院于2018年3月~2021年1月间收治的UAP患者119例，据入院单双号顺序将患者分为对照组（单号）和研究组（双号），对照组59例，接受单硝酸异山梨酯片治疗，研究组60例，接受参芍胶囊联合单硝酸异山梨酯片治疗。观察两组患者疗效、心功能指标、TLRs/MyD88/NF-κB信号通路相关指标表达、心绞痛发作次数和持续时间、心肌损伤指标及不良反应。结果：研究组治疗4周后的心电图疗效、临床疗效均优于对照组（P<0.05）。研究组治疗4周后的左心室射血分数（LVEF）高于对照组，左室舒张末期内径（LVEDD）、左心室收缩末期内径（LVESD）低于对照组（P<0.05）。研究组治疗4周后的心绞痛发作次数少于对照组，持续时间短于对照组（P<0.05）。研究组治疗4周后的心肌钙蛋白（cTnT）、肌酸激酶同工酶（CK-MB）和 N末端B型钠尿肽原（NT-proBNP）水平低于对照组（P<0.05）。研究组治疗4周后的TLRs2、TLRs4、NF-κB、MyD88表达量低于对照组（P<0.05）。对照组不良反应总发生率为8.47%，研究组为11.67%，组间对比无差异（P>0.05）。结论：单硝酸异山梨酯片与参芍胶囊联合治疗可有效缓解UAP患者心绞痛症状，保护患者心功能，阻止疾病进展，主要作用机制可能与下调TLRs/MyD88/NF-κB信号通路相关指标的表达有关。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the curative effect of Shenshao capsule combined with isosorbide mononitrate tablet in the treatment of unstable angina pectoris (UAP) and its effect on TLRs / MyD88 / NF-κB signaling pathway. Methods: 119 patients with UAP who were admitted in our hospital from March 2018 to January 2021 were selected, and divided into control group (single number) and study group (double number) according to the order of admission odd-even number. 59 patients in control group, they were treated with isosorbide mononitrate tablet, while 60 patients in study group, they were treated with Shenshao capsule combined with isosorbide mononitrate tablet. The curative effect, cardiac function indexes, TLRs/MyD88/NF-κB signaling pathway related expression, angina attack frequency and duration, myocardial injury indexes and adverse reactions in two groups were observed. Results: 4 weeks after treatment, the clinical efficacy and electrocardiogram efficacy of the study group were higher than those of the control group (P<0.05). 4 weeks after treatment, the left ventricular end systolic diameter (LVESD) and left ventricular end diastolic diameter (LVEDD) of the study group were lower than those of the control group, and the left ventricular ejection fraction (LVEF) of the study group was higher than that of the control group (P<0.05). 4 weeks after treatment, the number of angina attacks of the study group was less than that of the control group, and the duration was shorter than that of the control group (P<0.05). 4 weeks after treatment, the cardiac calcillin (cTnT), creatine kinase isoenzyme (CK-MB) and N-terminal B-type natriuretic peptide proBNP (NT-proBNP) of the study group were lower than those of the control group (P<0.05). 4 weeks after treatment, TLRs2, TLRs4, NF-κB and MyD88 of the study group were lower than those of the control group (P<0.05). The total incidence of adverse reactions was 8.47% of the control group, and 11.67% of the study group, and there was no difference between the two groups (P>0.05). Conclusion: Combined treatment with isosorbide mononitrate tablet and Shensha capsule can effectively relieve angina symptoms in patients with UAP, protect cardiac function, and prevent disease progression, and the main mechanism of action may be related to the down-regulation of TLRs/MyD88/NF-κB signaling pathway. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
